Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013;18(5):558-67.
doi: 10.1634/theoncologist.2012-0478. Epub 2013 May 13.

Perspectives on treatment of metastatic castration-resistant prostate cancer

Axel S Merseburger  1 , Joaquim Bellmunt, Cheryl Jenkins, Chris Parker, John M Fitzpatrick; European Treatment Practices Group
Affiliations
Review

Perspectives on treatment of metastatic castration-resistant prostate cancer

Axel S Merseburger et al. Oncologist. 2013.

Erratum in

  • Oncologist. 2013;18(6):775
  • Oncologist. 2013;18(8):971

Abstract

The arrival of several new agents--cabazitaxel, abiraterone acetate, enzalutamide, and radium-223--is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.

Keywords: Abiraterone acetate; Cabazitaxel; Docetaxel; Enzalutamide; Metastatic castration-resistant; Prostate cancer; Treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

Figure 1.
Figure 1.
Treatment algorithm for patients with metastatic castration-resistant prostate cancer who relapse after 6–8 cycles of docetaxel. Asterisks indicate treatment options that are affected by funding and availability in some countries. Abbreviations: mCRPC, metastatic castration-resistant prostate cancer; PSA DT, prostate-specific antigen doubling time.
Figure 2.
Figure 2.
Current and possible future sequencing of drugs in castration-resistant prostate cancer in Europe. Abbreviations: GNRH, gonadotropin-releasing hormone; LHRH, luteinizing hormone-releasing hormone; mCRPC, metastatic castration-resistant prostate cancer.
Figure 3.
Figure 3.
Treatment algorithm for older men with metastatic castration-resistant prostate cancer (≥70 years of age). Adapted from [93] with permission to include novel treatment options.* Abbreviations: CSIR-G, Cumulative Scoring Index Rating–Geriatrics; IADL, Instrumental Activities of Independent Daily Living.
See this image and copyright information in PMC

Comment in

  • IMPACT Study: Targeted Prostate Cancer Screening.
    Mikropoulos C, Eeles RA. Mikropoulos C, et al. Oncologist. 2013;18(8):e28. doi: 10.1634/theoncologist.2013-0221. Oncologist. 2013. PMID: 23986348 Free PMC article.
  • In reply.
    Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM. Merseburger AS, et al. Oncologist. 2014 Mar;19(3):305-6. doi: 10.1634/theoncologist.2013-0395. Epub 2014 Feb 17. Oncologist. 2014. PMID: 24536028 Free PMC article.
  • Resistance to "castration-resistant".
    Luzzatto L. Luzzatto L. Oncologist. 2014 Mar;19(3):305. doi: 10.1634/theoncologist.2013-0363. Epub 2014 Feb 17. Oncologist. 2014. PMID: 24536029 Free PMC article.

References

    1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
    1. Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–1907. - PubMed
    1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–781. - PubMed
    1. Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the year 2013. Ann Oncol. 2013;24:792–800. - PubMed
    1. Heidenreich A, Bastian PJ, Bellmunt J, et al. European Association of Urology: Guidelines on prostate cancer 2012. [Accessed April 5, 2013]. Available at http://www.uroweb.org/guidelines/online-guidelines/

Publication types

MeSH terms